ALLO – Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.ALLO
$1.82Name : Allogene Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $628,181,312.00
EPSttm : -0.77
Allogene Therapeutics, Inc.
$1.82
1.62%$0.03
ALLO — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
16.47
Margin Of Safety %
Put/Call OI Ratio
0.21
EPS Next Q Diff
0.02
EPS Last/This Y
0.23
EPS This/Next Y
-0.13
Price
1.84
Target Price
8.35
Analyst Recom
1.36
Performance Q
-32.84
Upside
-650.0%
Beta
0.49
Ticker: ALLO
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | ALLO | 2.3 | 0.32 | 0.03 | 29958 |
| 2026-05-12 | ALLO | 2.32 | 0.32 | 0.11 | 29896 |
| 2026-05-13 | ALLO | 2.33 | 0.33 | 0.11 | 28897 |
| 2026-05-14 | ALLO | 2.16 | 0.33 | 0.02 | 29267 |
| 2026-05-15 | ALLO | 2.01 | 0.26 | 0.69 | 28601 |
| 2026-05-18 | ALLO | 1.95 | 0.14 | 0.06 | 14451 |
| 2026-05-19 | ALLO | 1.89 | 0.14 | 0.03 | 15210 |
| 2026-05-20 | ALLO | 1.89 | 0.14 | 0.37 | 15404 |
| 2026-05-21 | ALLO | 1.96 | 0.14 | 0.00 | 15771 |
| 2026-05-22 | ALLO | 1.99 | 0.13 | 0.03 | 16237 |
| 2026-05-26 | ALLO | 2.13 | 0.13 | 0.02 | 16554 |
| 2026-05-27 | ALLO | 2.24 | 0.13 | 0.01 | 16709 |
| 2026-05-28 | ALLO | 2.25 | 0.13 | 0.03 | 16279 |
| 2026-05-29 | ALLO | 2.19 | 0.13 | 0.00 | 16467 |
| 2026-06-02 | ALLO | 2.05 | 0.12 | 14.47 | 17909 |
| 2026-06-03 | ALLO | 2 | 0.22 | 0.00 | 19548 |
| 2026-06-04 | ALLO | 2.03 | 0.22 | 0.01 | 19915 |
| 2026-06-05 | ALLO | 1.88 | 0.22 | 0.02 | 19876 |
| 2026-06-08 | ALLO | 1.86 | 0.21 | 0.08 | 20118 |
| 2026-06-09 | ALLO | 1.84 | 0.21 | 0.24 | 20153 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | ALLO | 2.30 | 35.7 | - | -0.67 |
| 2026-05-12 | ALLO | 2.32 | 35.7 | - | -0.67 |
| 2026-05-13 | ALLO | 2.32 | 35.7 | - | -0.67 |
| 2026-05-14 | ALLO | 2.16 | 35.7 | - | -0.67 |
| 2026-05-15 | ALLO | 2.01 | 35.7 | - | -0.67 |
| 2026-05-18 | ALLO | 1.95 | 35.7 | - | -0.67 |
| 2026-05-19 | ALLO | 1.89 | 35.7 | - | -0.67 |
| 2026-05-20 | ALLO | 1.89 | 35.7 | - | -0.66 |
| 2026-05-21 | ALLO | 1.96 | 35.7 | - | -0.66 |
| 2026-05-22 | ALLO | 2.00 | 30.6 | - | -0.66 |
| 2026-05-26 | ALLO | 2.13 | 29.4 | - | -0.64 |
| 2026-05-27 | ALLO | 2.24 | 29.4 | - | -0.64 |
| 2026-05-28 | ALLO | 2.25 | 29.4 | - | -0.64 |
| 2026-05-29 | ALLO | 2.19 | 29.4 | - | -0.64 |
| 2026-06-01 | ALLO | 2.15 | 29.4 | - | -0.64 |
| 2026-06-02 | ALLO | 2.05 | 29.4 | - | -0.64 |
| 2026-06-03 | ALLO | 2.00 | 29.4 | - | -0.64 |
| 2026-06-04 | ALLO | 2.02 | 29.4 | - | -0.64 |
| 2026-06-05 | ALLO | 1.88 | 29.4 | - | -0.64 |
| 2026-06-08 | ALLO | 1.86 | 29.4 | - | -0.64 |
| 2026-06-09 | ALLO | 1.84 | 29.4 | - | -0.64 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | ALLO | -0.23 | 0.08 | 17.56 |
| 2026-05-12 | ALLO | -0.23 | 0.08 | 17.79 |
| 2026-05-13 | ALLO | -0.23 | 0.08 | 17.79 |
| 2026-05-14 | ALLO | -0.23 | 0.08 | 17.79 |
| 2026-05-15 | ALLO | -0.23 | 0.08 | 15.36 |
| 2026-05-18 | ALLO | -0.30 | -0.46 | 14.53 |
| 2026-05-19 | ALLO | -0.31 | -0.46 | 14.53 |
| 2026-05-20 | ALLO | -0.31 | -0.46 | 14.53 |
| 2026-05-21 | ALLO | -0.31 | -0.46 | 14.53 |
| 2026-05-22 | ALLO | -0.31 | -0.46 | 14.53 |
| 2026-05-26 | ALLO | -0.31 | 7.32 | 14.42 |
| 2026-05-27 | ALLO | -0.32 | 7.32 | 14.42 |
| 2026-05-28 | ALLO | -0.32 | 7.32 | 16.54 |
| 2026-05-29 | ALLO | -0.32 | 7.32 | 16.54 |
| 2026-06-02 | ALLO | -0.32 | 7.14 | 16.54 |
| 2026-06-03 | ALLO | -0.32 | 7.14 | 16.54 |
| 2026-06-04 | ALLO | -0.32 | 7.14 | 16.47 |
| 2026-06-05 | ALLO | -0.32 | 7.14 | 16.47 |
| 2026-06-08 | ALLO | -0.32 | 7.15 | 16.47 |
| 2026-06-09 | ALLO | -0.32 | 7.15 | 16.47 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.18
Avg. EPS Est. Current Quarter
-0.16
Avg. EPS Est. Next Quarter
-0.15
Insider Transactions
-0.32
Institutional Transactions
7.15
Beta
0.49
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
9
Growth Score
22
Sentiment Score
7
Actual DrawDown %
93.4
Max Drawdown 5-Year %
-96.6
Target Price
8.35
P/E
Forward P/E
PEG
P/S
P/B
1.6
P/Free Cash Flow
EPS
-0.77
Average EPS Est. Cur. Y
-0.64
EPS Next Y. (Est.)
-0.77
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.78
Return on Equity vs Sector %
-89.8
Return on Equity vs Industry %
-73.6
EPS 1 7Days Diff
EPS 1 30Days Diff
0.03
EBIT Estimation
◆
ALLO
Healthcare
$1.82
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
35.6
Range 1M
8.6%
Sup Dist
3.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
17.8%
EPS NY
-12.4%
52W%
23.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+358.8% upside
Upside
+358.8%
Quality
9
Allogene Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 150
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
ALLO
Latest News
—
Caricamento notizie per ALLO…
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading